Prescribing overview
Proin formulations control canine urinary leakage from urethral sphincter hypotonus, not every cause of incontinence.
Key prescribing checks
- Investigate infection and other causes of incontinence; the label notes that Proin can mask infection signs and is not effective for incontinence from neurologic disease or malformations.
- Blood-pressure elevation is an important risk. Review cardiovascular disease, hypertension, kidney or liver disease and other conditions or drugs that increase that risk.
- Review sympathomimetics, tricyclic antidepressants, MAOIs and anesthetic planning. Secure flavored tablets because dogs can consume an entire bottle; suspected overdose needs urgent veterinary evaluation.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approvedUrinary incontinence due to urethral sphincter hypotonus
Exclude other causes; assess cardiovascular and renal risk.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Increases urethral smooth-muscle tone through adrenergic activity.
Absorption, distribution, metabolism and elimination
Dogs: Proin ER fed-state peak time 2–6 hours; elimination half-life 2.98–7.81 hours.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Proin
Dogs; chewable tablets.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Caution with heart disease, hypertension, hepatic disease, renal insufficiency, diabetes or glaucoma. It may mask urinary infection; reproductive safety has not been evaluated.
Proin ER
Dogs; extended-release tablets.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Caution with heart disease, hypertension, hepatic disease, renal insufficiency, diabetes or glaucoma. It may mask urinary infection; reproductive safety has not been evaluated.
- Dogs below 10 pounds cannot safely receive this presentation. Do not crush or split, or alternate with chewable tablets.
These labels present disease and drug-combination risks as precautions, without a separately headed contraindications section.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Hypertension, vomiting, weight loss, behavior changes and urinary retention are concerns.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsUrethral sphincter hypotonusProin chewable tablets | 2 mg/kg per dose Oral · Twice daily Individualized ongoing control | Calculate in half-tablet increments. Verify full dosing label ↗ |
| DogsUrethral sphincter hypotonusProin ER extended-release tablets | 2–4 mg/kg using the label weight-band tablet table Oral · Once daily Individualized ongoing control | At least 10 lb; with food; do not split/crush. Do not alternate with chewables. Verify full dosing label ↗ |
Confirm product-specific administration instructions before use.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Proin
Dogs; chewable tablets.
- Sympathomimetics, tricyclic antidepressants and MAO inhibitors can increase toxicity; halogenated inhaled anesthetics can increase arrhythmia risk.
Proin ER
Dogs; extended-release tablets.
- Sympathomimetics, tricyclic antidepressants and MAO inhibitors can increase toxicity; halogenated inhaled anesthetics can increase arrhythmia risk.
Monitoring
Monitor blood pressure, weight, appetite and urinary response; investigate infection.
Client counseling
Secure flavored tablets against overdose; contact a veterinarian immediately after excess ingestion.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Proin: 20–25°C; store securely.
Brands, formulations & ingredient identity
Active ingredients
Phenylpropanolamine
Other searchable names: Phenylpropanolamine hydrochloride · PPA
Proin contains phenylpropanolamine hydrochloride; PPA is a common abbreviation for the active ingredient.
Proin chewable tablets and Proin ER extended-release tablets contain the same drug but have different release characteristics and instructions.
Do not interchange chewable and ER products by ingredient name alone. Confirm the full product name, strength and prescription before dispensing.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Proin
- Formulation
- Oral chewable tablets
- Label / product scope
- Dogs
Immediate-release canine incontinence product; distinguish Proin ER.
Product label / source ↗Proin ER
- Formulation
- Extended-release oral tablets
- Label / product scope
- Dogs
Different release formulation; follow its own label and prescription.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →